Facebook
Twitter
LinkedIn
ForwardImplementation of a Prostate SBRT Program in the Community Setting (PRO 08)
Conventionally fractionated external beam radiation therapy (EBRT) has a long-standing track record of safety and excellent treatment outcomes in the management of all prostate cancer risk groups. With modern external beam radiation therapy techniques such as stereotactic body radiation therapy (SBRT) prostate cancer patients can now be treated safely with just a few fractions. SBRT is cost-effective and easy to implement in academic centers. With the recently announced PACE B primary outcome – that ultra-hypofractionated radiotherapy is non-inferior to standard radiotherapy for patients with low- and favorable intermediate-risk cancer, we expect that adoption of this regimen will accelerate further. Ultimately, whether SBRT can replace conventionally fractionated EBRT in the community is not known but is the topic of this activity. This activity is intended to guide the community practitioner in developing their own prostate SBRT practice. The activity begins with a discussion around the evidence supporting 5-fraction prostate SBRT. Next, we provide some guidance regarding practice management. The third speaker discusses how to safely deliver ultra-hypofractionated radiation in the community.
Target Audience
This activity is designed to meet the interests of medical oncologists, radiation oncologists, radiation physicists, nurses, radiation therapists, radiation dosimetrists, residents and specialists
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Be aware of the motivation and evidence for treating suitable prostate patients with SBRT.
- Feel confident in contouring, treatment planning and delivery of prostate SBRT. Be cognizant of tips to reducing side effects.
- Be familiar with approaches to building a successful community prostate SBRT program including advice on successful team building, marketing and reimbursement.
- Sean Philip Collins, MD, PhD, is employed by MedStar Georgetown University Hospital.
- Nicholas van As, MD, MB, is employed by The Royal Marsden NHS Foundation Trust.
- Jonathan Andrew Haas, MD, is employed by Perlmutter Cancer Center at New York University Langone Hospital - Long Island.
- Michael J. Zelefsky, MD, FASTRO, is employed by Memorial Sloan Kettering Cancer Center.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Meeting Steering Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.